AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21778609
Drug: Control: No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: No surface treatment
Trial: 19712032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (indication‐based guidelines for prescription of broad‐spectrum antimicrobials)
Trial: 16542207
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tramadol sustained release every 12 h for 12 weeks
Trial: 15145633
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate (single dose of about 10 mg/kg)
Trial: 15145633
Drug: Parenteral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral quinine (10 mg/kg at 0, 4, and 12 h)
Trial: 15145633
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate and parenteral quinine
Trial: 11180036
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 mg) coadministration with Sirolimus (10 mg)
Trial: 11180036
Drug: Sirolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (10 mg) alone
Trial: 11180036
Drug: Diltiazem (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120 mg) alone
Trial: 9597123
Drug: IL-1Ra treatment
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IL-1Ra treatment for six months
Trial: 2452393
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 x COPP + ABVD)
Trial: 2452393
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (3 x COPP + ABVD) with consolidation by radiotherapy (20 Gy IF)
Trial: 2452393
Drug: Including salvage
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Including salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 x CEVD in case of persisting disseminated disease)
Trial: 25550338
Drug: methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate monotherapy followed by add-on therapy with sulfasalazine and hydroxychloroquine
Trial: 25550338
Drug: methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate monotherapy followed by add-on therapy with infliximab
Trial: 25550338
Drug: initial methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: initial methotrexate therapy
Trial: 25550338
Drug: anti-CCP antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-CCP antibodies
Trial: 25550338
Drug: anti-cVim antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-cVim antibodies
Trial: 19615804
Drug: AST‐120 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST‐120 (6 g/d)
Trial: 19615804
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (low-protein diet and antihypertensive medication)
Trial: 15131439
Drug: Subset with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subset with somatization disorder in injection group
Trial: 9818106
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg ropivacaine
Trial: 9818106
Drug: 187.5 mg
RxNorm normalized name: terbinafine 187.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 187.5 mg ropivacaine
Trial: 9818106
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ropivacaine
Trial: 9818106
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg bupivacaine
Trial: 2651190
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg after dinner
Trial: 28937830
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg per day for 2 months)
Trial: 26561628
Drug: Low-fat, high-complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 polyunsaturated fatty acids (1.2 g/d)
Trial: 23832463
Drug: 4000 UI/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Trial: 23832463
Drug: 18000 UI/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18000 UI/week i.v. of epoetin alfa, beta or any other epoetin in equivalent doses
Trial: 19349313
Drug: Single-dose (21-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (21- or 35-mg) nicotine patch
Trial: 9413736
Drug: buspirone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (45 mg)
Trial: 7741805
Drug: High-dose vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vecuronium (0.3 mg kg ‐1)
Trial: 7741805
Drug: Suxamethonium (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium (1.0 mg kg ‐1)
Trial: 3948472
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cholestyramine 4 hours after HCTZ
Trial: 3948472
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of cholestyramine (-24, -12, and +4 hours after HCTZ)
Trial: 27384042
Drug: LEDT (photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEDT (photobiomodulation therapy using cluster light‐emitting diodes; 104 diodes; wavelength 660 and 850 nm; energy density 1.5 and 4.5 J/cm2; energy 60 J at each point; total energy delivered 600 J)
Trial: 23131207
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg dose of hemagglutinin (HA) antigen
Trial: 23131207
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg dose of hemagglutinin (HA) antigen
Trial: 12413434
Drug: Staphylococcus toxoid
RxNorm normalized name: Staphylococcus toxoid vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staphylococcus toxoid (SB) injections (0.1 ml to 1.0 ml weekly for 6 months)
Trial: 12413434
Drug: Staphylococcus toxoid
RxNorm normalized name: Staphylococcus toxoid vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staphylococcus toxoid (SB) injections
Trial: 1699088
Drug: Aprotinin treatment
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin treatment during cardiopulmonary bypass
Trial: 16256784
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment during cardiopulmonary bypass
Trial: 113627
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment attempts after initial therapy (Gp R)
Trial: 113627
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment attempts after initial therapy (Gp S)
Trial: 113627
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment attempts after initial therapy (Gp R/S)
Trial: 31896121
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake (total and intravenous)
Trial: 25547632
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and motor stimulation interventions (CMSI) administered by a single care provider
Trial: 23399084
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone pulses plus mycophenolate mofetil
Trial: 11076325
Drug: 4-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day antibiotic therapy
Trial: 19097848
Drug: 7-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day antibiotic therapy
Trial: 9103686
Drug: Microgynon (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon (combined pill)
Trial: 1568716
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of recombinant interferon‐alpha three times weekly for 12 weeks
Trial: 7259326
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion
Trial: 31941260
Drug: Terlipressin (1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1mg intravenous drip or static push every 6-12 hours for more than 5 days)
Trial: 29866141
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (CBT)
Trial: 27153076
Drug: Ergonomic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergonomic intervention (details on dosage and duration not specified)
Trial: 18479353
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg intravenously, 2 weeks before bed rest)
Trial: 12072899
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg)
Trial: 15854173
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day of mesalazine
Trial: 15854173
Drug: 1.2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/day of mesalazine
Trial: 10604820
Drug: Cotrimoxazole (TMP/SMX)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (TMP/SMX) 4 mg/kg TMP/20 mg/kg SMX at two divided doses for 5 days
Trial: 1685572
Drug: Controlled-release remoxipride
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release remoxipride (REM-CR), 361 mg daily
Trial: 1685572
Drug: Immediate-release remoxipride
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release remoxipride (REM-IR), 332 mg daily
Trial: 1685572
Drug: Haloperidol, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol, 12.5 mg daily
Trial: 31780765
Drug: Amfepramone (AFP)
RxNorm normalized name: amfepramone
DrugBank: Diethylpropion (DB00937)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amfepramone (AFP) 75 mg single dose
Trial: 21823222
Drug: Step 1
RxNorm normalized name: Nicotine Patch Step 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1 diet supplemented with soy food (SFD; 50 mg isoflavones per day)
Trial: 11528571
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis (AP) vaccine
Trial: 11528571
Drug: Licensed meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed meningococcal vaccine (MN)
Trial: 31140654
Drug: Day-and-night hybrid
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-and-night hybrid closed-loop insulin delivery using Cambridge FlorenceM system
Trial: 14616415
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg once daily)
Trial: 27310328
Drug: 2D regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily)
Trial: 27310328
Drug: 3D regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D regimen (ombitasvir/paritaprevir/ritonavir and dasabuvir 250 mg twice daily)
Trial: 22653713
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of calcium (as calcium carbonate)
Trial: 22653713
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of calcium
Trial: 20460997
Drug: Dexmedetomidine (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4, 0.6, and 0.8 ng/ml) as an adjunct to propofol-based TIVA
Trial: 20460997
Drug: Dexmedetomidine (0.6-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6-0.8 ng/ml) as an adjunct to propofol-based TIVA
Trial: 15699227
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing extracted soy isoflavones
Trial: 8996743
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefotiam + 500 mg metronidazole
Trial: 8996743
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefotiam + 500 mg metronidazole
Trial: 8487059
Drug: Immediate-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release morphine (IRM) solution (20 mg/mL)
Trial: 8487059
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine (SRM) formulation (30 mg)
Trial: 2512801
Drug: Moderate weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate weight gain (4-6 g.kg-1.d-1) - MG group
Trial: 2512801
Drug: Rapid weight
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid weight gain (12-16 g.kg-1.d-1) - RG group
Trial: 19223278
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aerobic exercise (20 min/day)
Trial: 19223278
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aerobic exercise (40 min/day)
Trial: 9010986
Drug: Dolasetron mesilate
RxNorm normalized name: Dolasetron mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesilate 1.2 mg/kg
Trial: 9010986
Drug: Metoclopramide 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 7 mg/kg
Trial: 8054248
Drug: Ethanol (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.80 g/kg body weight)
Trial: 10639202
Drug: Pulsed nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Trial: 10639202
Drug: Breath-synchronized nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath-synchronized nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Trial: 10639202
Drug: Constant output
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant output nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Trial: 8347899
Drug: Double-drug (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug (methylprednisolone and azathioprine)
Trial: 8347899
Drug: Triple-drug (methylprednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug (methylprednisolone, azathioprine, and cyclosporine)
Trial: 28988341
Drug: Axitinib monotherapy
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib monotherapy (AXI)
Trial: 27529317
Drug: Glucose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose group (infused with acetated Ringer's solution with glucose at 2 mg/kg/min)
Trial: 27529317
Drug: No glucose
RxNorm normalized name: No glucose hemofiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucose group (infused with acetated Ringer's solution without glucose)
Trial: 24841795
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg)
Trial: 24841795
Drug: Repeat doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg)
Trial: 24841795
Drug: Ozanezumab (0.01-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanezumab (0.01-15 mg/kg)
Trial: 24841795
Drug: Repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose 15 mg/kg ozanezumab
Trial: 24841795
Drug: Ozanezumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanezumab treatment
Trial: 23908486
Drug: Zoster vaccine
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoster vaccine (ZV)
Trial: 17682988
Drug: 15 infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 infusions of 1 mg/kg (group A)
Trial: 17682988
Drug: 15 infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 infusions of 0.75 mg/kg (group B)
Trial: 17682988
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 1 mg/kg (group C)
Trial: 17682988
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 0.75 mg/kg (group D)
Trial: 16287442
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL placebo
Trial: 9446843
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of water (control)
Trial: 9446843
Drug: 300 mL
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mL of table wine (28.4 g ethanol)
Trial: 9446843
Drug: 750 mL
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mL of table wine (71 g ethanol)
Trial: 67975
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered diamorphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Trial: 67975
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered morphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Trial: 25966305
Drug: Bicon(®) implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicon(®) implants (6 or 8 mm)
Trial: 25966305
Drug: Ankylos(®) implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankylos(®) implants (8 mm)
Trial: 22960769
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist started on day 1 of stimulation (Group 1)
Trial: 22960769
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist started on day 5 of stimulation (Group 2)
Trial: 20582874
Drug: GHRH injection
RxNorm normalized name: GHRH(1-44)
DrugBank: Somatorelin (DB12656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH injection (1 mu/kg body weight)
Trial: 17019083
Drug: FX06 injection
RxNorm normalized name: FX06
DrugBank: FX06 (DB05685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX06 injection during and immediately after primary PCI
Trial: 16061577
Drug: Outpatient family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient family therapy for 6 months
Trial: 16061577
Drug: Outpatient family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient family therapy
Trial: 12115176
Drug: CTLA‐4Ig (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA‐4Ig (0.5 mg/kg)
Trial: 12115176
Drug: CTLA‐4Ig (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA‐4Ig (2 mg/kg)
Trial: 12115176
Drug: CTLA‐4Ig (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTLA‐4Ig (10 mg/kg)
Trial: 12115176
Drug: LEA29Y (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEA29Y (0.5 mg/kg)
Trial: 12115176
Drug: LEA29Y (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEA29Y (2 mg/kg)
Trial: 12115176
Drug: LEA29Y (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEA29Y (10 mg/kg)
Trial: 10198864
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% drops (3 preoperative drops given 10 minutes apart)
Trial: 7774989
Drug: lovastatin 40‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 40‐80 mg once daily
Trial: 26928727
Drug: Polypill (containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (containing aspirin, statin and two antihypertensives)
Trial: 28341619
Drug: ERPonline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERPonline plus usual treatment